Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Study Overview

This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy.

Study Description

A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1b CLINICAL STUDY OF CMP 001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA

  • ClinicalTrials.gov Identifier: NCT02680184
  • Protocol Number: 16-377

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000